Latest Auxilium Pharmaceuticals (AUXL) Headlines
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
Auxilium Pharmaceuticals Earnings Hindsight: Down 2.0% in Last 10 Days (AUXL)
Comtex SmarTrend(R) - Mon Mar 10, 7:42AM CDT
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings a week ago on February 28th, 2014, analysts, on average, expected the company to report earnings of $0.21 on sales of $112.0 million. Auxilium Pharmaceuticals actually reported earnings of $0.27 per share on sales of $125.9 million, beating EPS estimates by $0.06 and beating revenue estimates by $13.9 million. Since the company's report, shares of Auxilium Pharmaceuticals have fallen from $30.75 to $30.14, representing a loss of 2.0% in the past 10 days.
Auxilium Pharmaceuticals Has Returned 46.8% Since SmarTrend Recommendation (AUXL)
Comtex SmarTrend(R) - Thu Mar 06, 11:00AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on December 6th, 2013 at $20.67. In approximately 3 months, Auxilium Pharmaceuticals has returned 46.77% as of today's recent price of $30.33.
Setback for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:55PM CST
Roche recently suffered a setback when it announced that an independent data monitoring committee has recommended that its phase III study, METLung, on onartuzumab (MetMab) should be stopped.
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
Auxilium Pharmaceuticals, Inc. To Present At The Barclay's Global Healthcare Conference
PR Newswire - Tue Mar 04, 5:30AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET on Tuesday, March 11, 2014.
Q4 Earnings Decline Y/Y at Endo, Weak Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 12:26PM CST
Earnings declined at Endo due to lower revenues.
Bayer Up on Higher Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:10AM CST
Bayer's earnings during the fourth quarter of 2013 came in at $1.50 compared with $1.31 in the year-ago period.
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
Cempra (CEMP) Falls: Stock Plunges 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:35AM CST
The shares of Cempra fell over 12% on the day. This breaks the recent trend of the company, as the stock is now trading within the volatile price range of $11.2 to $13.7 in the past one-month time frame. This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions.
Auxilium guidance cautious
at Investor's Business Daily - Fri Feb 28, 6:06PM CST
The drugmaker beat Q4 estimates as revenue fell 29% to $125.9 mil, topping consensus by about $14 mil. Auxilium Pharmaceuticals' (AUXL) EPS minus items rose 26% to 27 cents a share, beating by 5 cents. The year-ago 4th quarter included a 1-time...
Valeant Beats Earnings & Revs in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:49AM CST
Valeant reported fourth quarter 2013 cash earnings per share of $2.15, up from the year-ago earnings of 1.22 per share.
Auxilium Q4 Beats Estimates, But Guidance Cautious
at Investor's Business Daily - Fri Feb 28, 9:42AM CST
Auxilium Pharmaceuticals (AUXL) beat analysts' Q4 expectations but guided in line Friday morning. Auxilium shares were up more than 2% in early trading in the stock market today, hitting its highest point since May 2010. Revenue totaled $125.9...
Can The Uptrend Continue for Auxilium Pharmaceuticals (AUXL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 9:26AM CST
Can The Uptrend Continue for Auxilium Pharmaceuticals (AUXL)?
Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation
George Budwell, The Motley Fool - Motley Fool - Fri Feb 28, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Auxilium Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results And Guidance For 2014
PR Newswire - Fri Feb 28, 5:30AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.
Eli Lilly Gains Slightly on Dulaglutide Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 3:45PM CST
Eli Lilly announced encouraging data from the sixth phase III AWARD study on dulaglutide.
Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 10:10AM CST
Nektar reported a loss of 41 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 16 cents.
Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry
M2 - Tue Mar 11, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qpswzp/testosterone) has announced the addition of the "Concise Analysis of the International Testosterone Replacement Therapy (TRT) Industry" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Testosterone Replacement Therapy (TRT) in US$ Million. The global and the US markets are further analyzed by the following Product Segments: - Topicals - Patches - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 30 companies including many key and niche players such as: - AbbVie Inc. - Acrux Ltd. - Actavis, Inc. - Antares Pharma, Inc. - Auxilium Pharmaceuticals, Inc. - Bayer HealthCare Pharmaceuticals - Clarus Therapeutics Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview 3. Product Landscape 4. Testosterone Deficiency And Trt - An Overview 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Europe 4. Asia-Pacific 5. Latin America 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 30 (including Divisions/Subsidiaries - 36) - The United States (20) - Canada (4) - Japan (1) - Europe (7) - France (1) - Germany (1) - The United Kingdom (2) - Italy (1) - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) For more information visit http://www.researchandmarkets.com/research/qp...estosteron
Update on Endo's Product Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 11:00AM CDT
The approval of Aveed has boosted Endo's top line.
Auxilium Pharmaceuticals Earnings Hindsight: Down 2.0% in Last 10 Days (AUXL)
Comtex SmarTrend(R) - Mon Mar 10, 7:42AM CDT
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings a week ago on February 28th, 2014, analysts, on average, expected the company to report earnings of $0.21 on sales of $112.0 million. Auxilium Pharmaceuticals actually reported earnings of $0.27 per share on sales of $125.9 million, beating EPS estimates by $0.06 and beating revenue estimates by $13.9 million. Since the company's report, shares of Auxilium Pharmaceuticals have fallen from $30.75 to $30.14, representing a loss of 2.0% in the past 10 days.
Auxilium Pharmaceuticals Has Returned 46.8% Since SmarTrend Recommendation (AUXL)
Comtex SmarTrend(R) - Thu Mar 06, 11:00AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on December 6th, 2013 at $20.67. In approximately 3 months, Auxilium Pharmaceuticals has returned 46.77% as of today's recent price of $30.33.
Setback for Roche - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 2:55PM CST
Roche recently suffered a setback when it announced that an independent data monitoring committee has recommended that its phase III study, METLung, on onartuzumab (MetMab) should be stopped.
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Can Auxilium Pharma (AUXL) Continue to Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 7:30AM CST
Auxilium Pharma has seen its Zacks Rank surge over the past four weeks, moving from Hold territory to its current position as a Strong Buy.
Auxilium Pharmaceuticals, Inc. To Present At The Barclay's Global Healthcare Conference
PR Newswire - Tue Mar 04, 5:30AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET on Tuesday, March 11, 2014.
Q4 Earnings Decline Y/Y at Endo, Weak Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 12:26PM CST
Earnings declined at Endo due to lower revenues.
Bayer Up on Higher Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:10AM CST
Bayer's earnings during the fourth quarter of 2013 came in at $1.50 compared with $1.31 in the year-ago period.
Auxilium Pharma Beats on Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 10:00AM CST
Revenues were boosted by the recently acquired subsidiary, Actient, as well as higher Xiaflex sales in the U.S.
Cempra (CEMP) Falls: Stock Plunges 12.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 7:35AM CST
The shares of Cempra fell over 12% on the day. This breaks the recent trend of the company, as the stock is now trading within the volatile price range of $11.2 to $13.7 in the past one-month time frame. This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions.
Auxilium guidance cautious
at Investor's Business Daily - Fri Feb 28, 6:06PM CST
The drugmaker beat Q4 estimates as revenue fell 29% to $125.9 mil, topping consensus by about $14 mil. Auxilium Pharmaceuticals' (AUXL) EPS minus items rose 26% to 27 cents a share, beating by 5 cents. The year-ago 4th quarter included a 1-time...
Valeant Beats Earnings & Revs in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:49AM CST
Valeant reported fourth quarter 2013 cash earnings per share of $2.15, up from the year-ago earnings of 1.22 per share.
Auxilium Q4 Beats Estimates, But Guidance Cautious
at Investor's Business Daily - Fri Feb 28, 9:42AM CST
Auxilium Pharmaceuticals (AUXL) beat analysts' Q4 expectations but guided in line Friday morning. Auxilium shares were up more than 2% in early trading in the stock market today, hitting its highest point since May 2010. Revenue totaled $125.9...
Can The Uptrend Continue for Auxilium Pharmaceuticals (AUXL)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 9:26AM CST
Can The Uptrend Continue for Auxilium Pharmaceuticals (AUXL)?
Today's Top Biotech Stories: Ampio Pharmaceuticals, Auxilium Pharmaceuticals, Bayer, and Medivation
George Budwell, The Motley Fool - Motley Fool - Fri Feb 28, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Auxilium Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results And Guidance For 2014
PR Newswire - Fri Feb 28, 5:30AM CST
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.
Eli Lilly Gains Slightly on Dulaglutide Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 3:45PM CST
Eli Lilly announced encouraging data from the sixth phase III AWARD study on dulaglutide.
Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 10:10AM CST
Nektar reported a loss of 41 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 16 cents.
